- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03106935
Recurrent Pregnancy Loss and Thyroid Disease
Effect of Levothyroxine Treatment on Pregnancy Outcome in RPL Women With Subclinical Hypothyroidism
The present study is divided into two groups ,one is the patients with subclinical hypothyroidism who has TPO antibody positive women with TSH concentrations > 2.5 mU/L and below the upper limit of the pregnancy specific reference range ,another is TPO antibody negative with TSH concentrations greater than the pregnancy specific reference range and below 10.0 mU/L.The two groups are randomized into either the LT4 treatment group or control group by the use of a computer-generated list.
The aim of our study is to determine whether the use of levothyroxine is beneficial in patients with subclinical hypothyroidism in two groups。
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215004
- Second Affiliated Hospital of Soochow University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- having a diagnosis of RPL (two or more consecutive or non-consecutive first-trimester losses)
- be.ing aged 18-39 years at randomisation
- trying to conceive naturally
- willing and able to give informed consent
Exclusion Criteria:
- they were unable to conceive naturally (as confirmed by urinary pregnancy tests) within 1 year of recruitment or before the end of the randomisation period in the trial, whichever came earlier
- they had antiphospholipid syndrome [lupus anticoagulant and/or anticardiolipin antibodies (immunoglobulin G or immunoglobulin M)]; other recognised thrombophilic conditions (testing according to usual clinic practice) l they had uterine cavity abnormalities (as assessed by ultrasound, hysterosonography, hysterosalpingogram or hysteroscopy)
- they had abnormal parental karyotype
- they had other identifiable causes of RPL (tests initiated only if clinically indicated) such as diabetes or systemic lupus erythematosus
- they had any contraindications to Levothyroxine use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Obstet Gynecol,SecondSoochowU
Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2
0.2-3.0mIU/L,
T3 0.3-3.0mIU/L) .
|
Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2
0.2-3.0mIU/L,
T3 0.3-3.0mIU/L) .
Other Names:
|
NO_INTERVENTION: reproductive center,SecondSoochowU
For the control group ,women with subclinical hypothyroidism are not given any drugs .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gestational week at delivery
Time Frame: 28 weeks
|
The research doctor site telephoned every participant 2 weeks after the expected date of delivery to obtain pregnancy outcome data.
|
28 weeks
|
Newborn birth weight
Time Frame: at birth
|
The research doctor site telephoned every participant 2 weeks after the expected date of delivery to obtain newborn birth weight.
|
at birth
|
APGAR Score at birth
Time Frame: at birth
|
The APGAR (Appearance, Pulse, Grimace, Activity, Respiration) scale is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained.
The resulting APGAR score ranges from zero to 10.
|
at birth
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of clinical pregnancy at 6-8 weeks (defined as the presence of a gestational sac, with or without a yolk sac or fetal pole)
Time Frame: 8 weeks
|
The research doctor site telephoned every participant at between 6 and 7 weeks of gestation, to ensure there were arrangements for an ultrasound appointment with her usual carers, before 8 weeks of gestation.
If an appointment had not been booked, the research doctor assisted with booking.
The research doctor telephoned each participant again between 3 and 5 days after the scheduled date of the ultrasound appointment, to obtain details of the observations of a gestational sac.
|
8 weeks
|
Number of ongoing pregnancy at 12 weeks (defined as the presence of a fetal heartbeat)
Time Frame: 12weeks
|
The research doctor site telephoned each participant between 10 and 12 weeks of gestation, to ensure there were arrangements for an ultrasound appointment with her usual carers, at between 12 and 14 weeks of gestation.
As previously, the research doctor assisted with booking an appointment if necessary, and telephoned the participant afterwards to obtain details of variables such as fetal heartbeat.
The research doctor also recorded the expected date of delivery at this stage.
|
12weeks
|
Number of miscarriage (defined as loss of pregnancy before 28 weeks of gestation).
Time Frame: 28 weeks
|
The research doctor site telephoned each participant before28 weeks of gestation, to obtain their pregnancy outcomes such as miscarriage.
|
28 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: ZHANG Hong, Ph.D,M.D, a staff of The Second Affiliated Hospital of Soochow University
Publications and helpful links
General Publications
- Zhu LY, Chen X, Xu ZZ, Xu L, Mao T, Zhang H. Changes and clinical significance of peripheral blood helper T lymphocyte and natural killer (NK) cells in unexplained recurrent spontaneous abortion (URSA) patients after abortion and successful pregnancy. Clin Exp Obstet Gynecol. 2015;42(1):62-6.
- Wu S, Zhang H, Tian J, Liu L, Dong Y, Mao T. Expression of kisspeptin/GPR54 and PIBF/PR in the first trimester trophoblast and decidua of women with recurrent spontaneous abortion. Pathol Res Pract. 2014 Jan;210(1):47-54. doi: 10.1016/j.prp.2013.09.017. Epub 2013 Oct 26.
- Zhang H, Long Q, Ling L, Gao A, Li H, Lin Q. Elevated expression of KiSS-1 in placenta of preeclampsia and its effect on trophoblast. Reprod Biol. 2011 Jul;11(2):99-115. doi: 10.1016/s1642-431x(12)60048-5.
- Mao C, Zhang H, Xiao D, Zhu L, Ding Y, Zhang Y, Wu L, Xu Z, Zhang L. Perinatal nicotine exposure alters AT 1 and AT 2 receptor expression pattern in the brain of fetal and offspring rats. Brain Res. 2008 Dec 3;1243:47-52. doi: 10.1016/j.brainres.2008.09.060. Epub 2008 Oct 2.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- The Second Affiliated Hospital
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Pregnancy Loss
-
University Hospital, ToulouseCompleted
-
Wake Forest University Health SciencesWithdrawnRecurrent Pregnancy Loss Without Current Pregnancy
-
Bagcilar Training and Research HospitalCompletedRecurrent Pregnancy Loss Without Current PregnancyTurkey
-
Caroline Nørgaard-PedersenDepartment of Clinical Immunology, Odense University Hospital, DK; Department...RecruitingRecurrent Pregnancy Loss, Not PregnantDenmark
-
Mỹ Đức HospitalNot yet recruitingVaginal Microbiome | Recurrent Pregnancy Loss, Not Pregnant
-
Nora Therapeutics, Inc.UnknownRecurrent Miscarriage | Recurrent Pregnancy LossUnited Kingdom
-
Soroka University Medical CenterUnknownRecurrent Miscarriage | Recurrent Pregnancy Loss(RPL)Israel
-
Peking University Third HospitalCompletedRecurrent Early Pregnancy LossChina
-
Ain Shams UniversityCompletedRecurrent Pregnancy LossEgypt
-
Institute of Biophysics and Cell Engineering of...Belarusian Medical Academy of Post-Graduate EducationNot yet recruiting
Clinical Trials on Levothyroxine
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulUnknownAging | Interaction Drug Food | Primary HypothyroidismBrazil
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedPregnancy | Subclinical Hypothyroidism | HypothyroxinemiaUnited States
-
Boston Children's HospitalCompleted
-
University of California, Los AngelesTerminatedHypothyroidismUnited States
-
Walter Reed National Military Medical CenterUnknown
-
Centre Hospitalier Universitaire de NiceWithdrawnSubclinical hypothyroïdismFrance
-
GlaxoSmithKlineCompletedHypothyroidismIndia
-
Assaf-Harofeh Medical CenterCompleted
-
Nova Scotia Health AuthorityNot yet recruitingSecondary Hypothyroidism
-
Ain Shams UniversityUnknown